Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This statement is a FSRH CEU response to a public consultation conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding licensing of two brands of desogestrel 75mcg progestogen-only pill (POP) as Pharmacy Medicines (P). The products are Hana® (Laboratoire HRA Pharma) and Lovima® (Maxwellia Ltd).
FSRH, along with fellow Royal colleges, charities, and health bodies have written to Health and Social Care Secretary Matt Hancock to call for more support for health and care professionals to identify signs of domestic abuse, and to signpost adult and child victims of domestic abuse to appropriate support services.
On 24 April the Medicines and Healthcare Products Regulatory Agency (MHRA) changed its regulatory position on medicines containing sodium valproate. MHRA advises that if a woman of childbearing age is to be prescribed sodium valproate, she must be enrolled in a pregnancy prevention programme (PPP). This FSRH statement outlines the implications for daily practice.
Comment submitted by FSRH along with open letter to Secretary of State for Health Jeremy Hunt regarding the NHS Charges to Overseas Visitors Amendment Regulations 2017
Read and download the full response to the Independent Inquiry into Child Sexual Abuse.
FSRH Statement expressing concern for women's health and opportunities following the reinstatement of the Mexico City Policy
Today (24.10.2016) the Academy of Medical Royal Colleges is launching its Choosing Wisely campaign and website, with a list of forty treatments and procedures that are of little or no benefit to patients.
FSRH Submission to Government's consultation on reporting child abuse and neglect
FSRH welcomes the opportunity to respond to this consultation on proposed 100% Business Rate Retention.
FSRH welcomes the opportunity to respond to the Fair Funding Review.
